Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

administered daily. Patients in the first cohort will receive a dose of XL184 that is below the maximum tolerated dose (MTD) identified in the ongoing phase 1 trial of XL184, in combination with erlotinib. Subsequent cohorts will receive erlotinib in combination with escalating doses of XL184 until the MTD is reached. In the phase 2 portion of the study, patients will be randomized to receive XL184 at the MTD alone or in combination with erlotinib. Additionally, correlative studies will evaluate MET amplification and EGFR mutational status. MET and EGFR signaling activity will be assessed in tumor and surrogate tissue.

Data from an ongoing phase 1 trial of XL184 in patients with advanced malignancies were presented in October 2007 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract #A152). Investigators reported that anti-tumor activity had been observed in a variety of cancers at doses that are not associated with significant toxicity. There were 33 patients available for safety, pharmacokinetic and tumor response analyses as of the June 22, 2007 cutoff; further data were also provided for six additional patients after the cutoff. Of seven patients with medullary thyroid cancer (MTC), three had partial responses (two confirmed and one unconfirmed) as of the date of the AACR-NCI- EORTC Conference. In addition, as of such date, six of the seven patients had tumor shrinkage and one had non-measurable disease. All seven assessable patients with MTC experienced a rapid decrease in plasma levels of calcitonin, a marker frequently elevated in MTC, and six of the seven patients had a decrease in the tumor marker carcinoembryonic antigen. All seven MTC patients remain on study. In addition, one patient with a neuroendocrine tumor has an unconfirmed partial response. In total, 15 patients with various malignancies have had stable disease lasting from 3 - 20 months, including nine patients with stable disease for m
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and PITTSBURGH , July 27, 2015 ... it will hold its extraordinary general meeting of shareholders in ... PRGO ; TASE) at the Okura Hotel Amsterdam on ... (CET). Among other agenda items at the ... the approval, under article 2:107a of the Dutch Civil Code, ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rq47bp/global_pressure ... Pressure Relief Devices Market 2015-2019" report to their ... to grow at a CAGR of 4.41% over the ... Market 2015-2019, has been prepared based on an in-depth ... covers the Americas, and the APAC and EMEA; it ...
(Date:7/27/2015)... PLEASANTON, Calif. , July 27, 2015  QT ... the "Group"), a global company engaged in the design, ... minimally invasive treatment of vascular disease, has entered into ... for up to US$13.14 million convertible bond investment. This ... help boost its growth to the next milestone. ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece published July ... of plastic surgery and explained why people should not shy away from their own ... excesses of the few and celebrate it for the modern wonder that it is.” ...
(Date:7/27/2015)... ... ... North Central Surgical Center Hospital will be holding twice-monthly joint wellness classes for ... along with their friends and family members, to attend. The classes take place on ... [Tue due to Labor Day], Oct 5, Nov 2, Dec 7) beginning at 9 ...
(Date:7/27/2015)... ... 27, 2015 , ... A Harris County jury awarded a group of Texas ... promoter Robert Kubbernus based on findings of fraud and violations of the Texas Securities ... court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, Inc. and ...
(Date:7/27/2015)... ... 2015 , ... BESLER Consulting today announced the publication of ... Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP with ... the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights that ...
(Date:7/27/2015)... ... 2015 , ... For a limited time, Huntington Beach dentist , Dr. ... a great time to change up a look or to simply brighten a smile. ... your self-esteem. Over time, the enamel coating can become worn and can expose more ...
Breaking Medicine News(10 mins):Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3
... are known to be good for lowering cholesterol and ... reported benefit: they appear to slow decline in lung ... According to researchers in Boston, it may be statins ... , Their findings were published in the second issue ...
... hire an ad agency; at,least not initially especially if you ... an agency can,t come up with something great. It,s,just that ... Most clients follow tradition process in attempting to find ... develop a,short list of 3 agencies and ask for a ...
... Educate Chicagoans, CHICAGO, Oct. 11 Continuing ... of Chicago, SAVE THE PATIENT, a,not-for-profit patient-focused organization, ... Chicago Access Network. "Community Health Hotline" will,air Monday, ... 21., Monday,s program will feature a frank ...
... /Xinhua-PRNewswire/ -- On,October 10, 2007, Synutra International, Inc. ... dairy-based nutritional products,for infants, children and adults, received ... the Company,s common stock is no longer subject ... October 5, 2007 of the,Company,s quarterly report on ...
... Monday will be a little,cooler for the patients ... the entire Washington Capitals team will make their annual,visit. ... raise money for,cancer research, Courage Caps., Courage Caps ... the season at Capitals home games and online at ...
... who overcome breast cancer have every reason to celebrate. ... a heart damaged by life-saving cancer therapies, a growing ... today including new treatments still under development ... Jones, Ph.D., an exercise physiologist and assistant professor in ...
Cached Medicine News:Health News:Statins reduce loss of function, keeping old lungs young - even in smokers 2Health News:A New Way to Discover Marketing Ideas 2Health News:Patient Empowerment -- Medication Error 2Health News:Nasdaq Informs Synutra that the Company's Filing Delinquency has been Cured 2Health News:Breast cancer awareness calls for cardiovascular awareness 2Health News:Breast cancer awareness calls for cardiovascular awareness 3
... For delivery of medication as well as ... refillable, closed dilution, high volume, continuous medication ... therapy to patients. Its 200 ml reservoir ... to 8 hours of nebulized medication delivery ...
Nebulizer Adapter Kit 6"...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
Medicine Products: